AU2014231330A1 - Small molecule modulators of PCSK9 and methods of use thereof - Google Patents

Small molecule modulators of PCSK9 and methods of use thereof Download PDF

Info

Publication number
AU2014231330A1
AU2014231330A1 AU2014231330A AU2014231330A AU2014231330A1 AU 2014231330 A1 AU2014231330 A1 AU 2014231330A1 AU 2014231330 A AU2014231330 A AU 2014231330A AU 2014231330 A AU2014231330 A AU 2014231330A AU 2014231330 A1 AU2014231330 A1 AU 2014231330A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
substituted
amino
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014231330A
Other languages
English (en)
Inventor
Jean-Francois Chiasson
Sheldon Crane
Daniel Guay
Nicolas Lachance
Patrick Lacombe
Nabil G. Seidah
Kathryn Skorey
Vouy Linh Truong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMORCHEM HOLDINGS Inc
Adaerata LP
Original Assignee
AMORCHEM HOLDINGS Inc
Adaerata LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMORCHEM HOLDINGS Inc, Adaerata LP filed Critical AMORCHEM HOLDINGS Inc
Publication of AU2014231330A1 publication Critical patent/AU2014231330A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Crystallography & Structural Chemistry (AREA)
AU2014231330A 2013-03-15 2014-03-14 Small molecule modulators of PCSK9 and methods of use thereof Abandoned AU2014231330A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792249P 2013-03-15 2013-03-15
US61/792,249 2013-03-15
PCT/CA2014/050255 WO2014139008A1 (en) 2013-03-15 2014-03-14 Small molecule modulators of pcsk9 and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2014231330A1 true AU2014231330A1 (en) 2015-10-01

Family

ID=51535727

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014231330A Abandoned AU2014231330A1 (en) 2013-03-15 2014-03-14 Small molecule modulators of PCSK9 and methods of use thereof

Country Status (10)

Country Link
US (1) US20160031935A1 (cg-RX-API-DMAC7.html)
EP (1) EP2961765A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016511274A (cg-RX-API-DMAC7.html)
KR (1) KR20150132362A (cg-RX-API-DMAC7.html)
CN (1) CN105431447A (cg-RX-API-DMAC7.html)
AU (1) AU2014231330A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023761A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905237A1 (cg-RX-API-DMAC7.html)
HK (1) HK1222864A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014139008A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016029037A1 (en) 2014-08-21 2016-02-25 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity
US20170290806A1 (en) * 2014-09-08 2017-10-12 Temple University-Of The Commonwealth System Of Higher Education PCSK9 Inhibitors and Methods of Use Thereof
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2017281332A1 (en) 2016-06-24 2018-12-20 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
GB2567210B (en) 2017-10-06 2020-01-15 Rolls Royce Plc A bladed disk
CN109096247A (zh) * 2018-08-15 2018-12-28 上海罕道医药科技有限公司 一种3h双吖丙啶基双取代吡啶衍生物的制备方法
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
LV15544A (lv) * 2019-07-01 2021-01-20 Latvijas Organiskās Sintēzes Institūts Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori
WO2024163598A2 (en) * 2023-01-31 2024-08-08 Brandeis University Peptides comprising thioester groups, including depsipeptide thioesters, methods of making, and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180586B1 (en) * 1996-09-24 2001-01-30 The Procter & Gamble Company Liquid laundry detergent compositions containing proteolytic enzyme and protease inhibitors
GB9623908D0 (en) * 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
US7691967B2 (en) * 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
AR066042A1 (es) * 2007-04-13 2009-07-22 Novartis Ag Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
AR079344A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AU2011223795B2 (en) * 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR20140132367A (ko) * 2012-02-16 2014-11-17 알큐엑스 파마슈티컬스, 인크. 선형 펩티드 항생제

Also Published As

Publication number Publication date
JP2016511274A (ja) 2016-04-14
WO2014139008A1 (en) 2014-09-18
EP2961765A1 (en) 2016-01-06
EP2961765A4 (en) 2016-11-09
BR112015023761A2 (pt) 2017-07-18
CA2905237A1 (en) 2014-09-18
HK1222864A1 (zh) 2017-07-14
US20160031935A1 (en) 2016-02-04
KR20150132362A (ko) 2015-11-25
CN105431447A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
US20160031935A1 (en) Small molecule modulators of pcsk9 and methods of use thereof
US11692008B2 (en) Preparation and uses of reactive oxygen species scavenger derivatives
CN110809467B (zh) Sestrin-gator2相互作用的调节剂及其用途
CN102471248B (zh) 用于递送1,3-丙二磺酸的方法、化合物和组合物
US11312703B2 (en) Reactive oxygen species scavengers and use for treating diseases
RS63714B1 (sr) Jedinjenja koja sadrže nitril korisna kao antivirusna sredstva za lečenje infekcije koronavirusom
AU2018205019C1 (en) Inhibitors of transglutaminases
US11980609B2 (en) LPA receptor antagonists and uses thereof
JP7753201B2 (ja) プロテインキナーゼc(pkc)に作用するジテルペノイド化合物
KR20100126762A (ko) 세포내 효소 및 수용체 조절
CA2892368A1 (en) Ketoamide immunoproteasome inhibitors
CN108239073A (zh) 化合物、医药组成物及其用途
JP2019507176A (ja) Htra1阻害剤としての新規ジフルオロケタミド誘導体
US20150232420A1 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
JP7774915B2 (ja) アミノ酸活性エステル及びその塩
CN118546122A (zh) 一类靶向降解tead的化合物及其制备方法和应用
TW202417422A (zh) N-(2-(3-氰基-2-氮雜雙環[3.1.0]己-2-基)-2-側氧基乙基)- 喹啉-4-甲酼胺
HK40029856B (en) Preparation and uses of reactive oxygen species scavenger derivatives
HK40029856A (en) Preparation and uses of reactive oxygen species scavenger derivatives
WO2019184744A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
WO2018177861A1 (en) Symmetrical tris-aryl-amide derivatives and their use as anti-heparanase
HK40021802B (en) Preparation and use of reactive oxygen species scavenger
HK40021802A (en) Preparation and use of reactive oxygen species scavenger

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application